BRCA in breast cancer: ESMO clinical recommendations.
Balmaña
J
J
Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
Díez
O
O
Castiglione
M
M
D051017:Apoptosis Regulatory Proteins; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D001943:Breast Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000628:therapy; D064447:Checkpoint Kinase 2; D005060:Europe / Q000453:epidemiology; D005260:Female; D005820:Genetic Testing / Q000379:methods / Q000592:standards; D006287:Health Planning Guidelines; D006801:Humans; D009154:Mutation / Q000235:genetics; D051059:PTEN Phosphohydrolase / Q000235:genetics; D015995:Prevalence; D017346:Protein Serine-Threonine Kinases / Q000235:genetics; D012955:Societies, Medical / Q000592:standards*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
D051017:Apoptosis Regulatory Proteins; C118024:BLID protein, human; D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D064447:Checkpoint Kinase 2; C578634:CHEK2 protein, human; D017346:Protein Serine-Threonine Kinases; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human